Compositions and methods for combined therapy of disease

Details Compositions and methods for combined therapy of disease Compositions and methods for combined therapy of disease

2004-12-23

2010-10-05

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C536S024310, C536S024330, C514S04400A, C435S320100

Reexamination Certificate

active

07807814

ABSTRACT:
A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to increase expression from at least one second gene. The reduced expression of the first gene and the increased expression from the second gene in the target cells induces the desired physiological state in the subject. By altering target cell gene expression in this way, conditions such as angiogenesis or tumor growth and metastasis can be inhibited.

REFERENCES:
patent: 7153667 (2006-12-01), Shen et al.
patent: 7217572 (2007-05-01), Ward et al.
patent: 2003/0069195 (2003-04-01), Farrar et al.
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0216335 (2003-11-01), Lockridge et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0019927 (2005-01-01), Hildinger et al.
patent: 2005/0220768 (2005-10-01), McVey et al.
patent: 2006/0216295 (2006-09-01), Crabtree et al.
patent: 2007/0155686 (2007-07-01), Akine et al.
patent: 2007/0155690 (2007-07-01), Chatterton et al.
patent: WO 03/063904 (2003-08-01), None
patent: WO 03/085110 (2003-10-01), None
patent: WO 03/099298 (2003-12-01), None
patent: WO 2005/032486 (2005-04-01), None
patent: WO 2005/035759 (2005-04-01), None
patent: WO 2006/038208 (2006-04-01), None
patent: WO 2006/110813 (2006-10-01), None
Hammond et al., Post-Transcriptional Gene Silencing by Double-Stranded RNA, 2001, Nature Reviews, Genetics, vol. 2, pp. 110-119.
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Filleur et al., SiRNA-mediated Inhibition of Vascular Endothelial Growth Factor Severely Limits Tumor Resistance to Antiangiogenic Thrombospondin-1 and Slows Tumor Vascularization and Growth, Jul. 15, 2003, Cancer Research, 63, pp. 3919-3922.
Dawson et al., Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis, 1999, Science, 285, pp. 245-248.
Kim et al., 8-CL-Camp Induces Cell Cycle-Specific Apoptosis in Human Cancer Cells, 2001, Int. J. Cancer 93:33-41.
Zhang et al., Vector-based RNAi, a ovel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer, 2003, Biochem. Biophys. Res. Comm. 303:1169-1178.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Curr. Pharmaceutical Biotech. 5(1):1-7.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, 2005, Expert Opin. Drug Deliv. 2(1):3-28.
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nature Biotech. 21(12):1457-1465.
Yin et al., siRNA agents inhibit oncogene expression and attenuate human tumor cell growth, 2003, J. Exp. Therap. and Oncol. 3:194-204.
Sun et al., Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy, 2001, Gene Therapy 8;638-645.
Reich et al., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model, 2003, Mol, Vision 9;210-216.
Caplen, RNAi as a gene therapy approach, 2003, Expert Opin. Biol. Ther, 3(4):575-586.

Affiliated with

Also associated with

Rating

Compositions and methods for combined therapy of disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for combined therapy of disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for combined therapy of disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4220014